Journal of Pathology and Translational Medicine

Original Article

Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution: Meejeong Kim, Hee Sang Hwang, Hyungwoo Cho, Dok Hyun Yoon, Cheolwon Suh, Chan Sik Park, Heounjeong Go, Jooryung Huh; J Pathol Transl Med. 2021;55(5):330-337. Published online September 2, 2021; DOI: https://doi.org/10.4132/jptm.2021.07.25

3,443 View
108 Download
4 Web of Science
5 Crossref

Background
Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma (NHL) in Western countries. However, it is relatively rare in Asia. This study examined epidemiologic characteristics of FL in South Korea, with an emphasis on recent trends of increase in cases.
Methods
We retrospectively examined 239 cases of newly diagnosed FL at a large tertiary institution in Korea (Asan Medical Center, Seoul, Republic of Korea) between 2008 and 2017. Age-adjusted incidence rates and clinicopathological variables were analyzed, and joinpoint regression analysis was used to identify the changes.
Results
The age-adjusted incidence of FL significantly increased during the study period (p = .034), and the ratio of (relative incidence) patients with FL to patients with NHL increased from 4.28% to 9.35% in the same period. Over the 10-year study assessment duration, the proportion of patients with stage III/IV FL (p = .035) and expression of BCL2 (p = .022) or BCL6 (p = .039) significantly increased. From 2013–2017, the proportion of patients with highrisk Follicular Lymphoma International Prognostic Index (FLIPI) score increased (21.5% to 28.7%), whereas that of low-risk FLIPI decreased (55.4% to 38.6%), although those results were not statistically significant (p = .066).
Conclusions
We found an increasing incidence of FL, with a disproportionate increase in the incidence of high-stage disease and recent changes in the clinicopathologic features of the Korean patient population.

Citations

Citations to this article as recorded by

Incidence Trend of Follicular Lymphoma in Taiwan Compared to Japan and Korea, 2001–2019
Liang-Chun Chiu, Chih-Wen Lin, Hung-Ju Li, Jian-Han Chen, Fu-Cheng Chuang, Sheng-Fung Lin, Yu Chang, Yu-Chieh Su
Journal of Clinical Medicine.2023; 12(4): 1417. CrossRef
A Case Report on the Complete Response of a Patient with Recurrent Follicular Lymphoma Treated with Integrative Medicine
Kyung-dug Park, Jisoo Kim, Yoona Oh, Beom-Jin Jeong, Yu-jin Jung, Sunhwi Bang
The Journal of Internal Korean Medicine.2023; 44(3): 585. CrossRef
Recent Updates on Diagnosis and Treatment of Follicular Lymphoma
Ga-Young Song, Deok-Hwan Yang
The Korean Journal of Medicine.2023; 98(5): 231. CrossRef
Classical Hodgkin lymphoma following follicular lymphoma: a case report
Bomi Kim
Journal of Yeungnam Medical Science.2023; 40(Suppl): S113. CrossRef
Incidence, clinicopathological features and genetics of in‐situ follicular neoplasia: a comprehensive screening study in a Japanese cohort
Naoki Oishi, Takahiro Segawa, Kunio Miyake, Kunio Mochizuki, Tetsuo Kondo
Histopathology.2022; 80(5): 820. CrossRef

Brief Case Report

Breast implant–associated anaplastic large cell lymphoma: the first South Korean case: Jongwon Lee, Hyungwoo Cho, Dok Hyun Yoon, Eun Key Kim, Gyungyub Gong, Cheolwon Suh, Joo-ryung Huh; J Pathol Transl Med. 2020;54(5):432-434. Published online August 18, 2020; DOI: https://doi.org/10.4132/jptm.2020.07.01

3,997 View
133 Download
5 Web of Science
5 Crossref

PDF

Citations

Citations to this article as recorded by

Breast Reconstruction after Breast Implant-Associated Anaplastic Large Cell Lymphoma Treatment: A Case Report and Literature Review
Won-Seob Lee, Tae-Gon Kim, Jun-Ho Lee, Il-Kug Kim
Journal of Clinical Medicine.2023; 12(5): 1885. CrossRef
Breast filler granuloma mistaken for implant rupture: A case report
Yong Seon Hwang, Je Yeon Byeon, Jun Hyuk Kim, Hwan Jun Choi, Mee Hye Oh, Da Woon Lee
Medicine.2023; 102(22): e33785. CrossRef
Implant replacement and anaplastic large cell lymphoma associated with breast implants: a quantitative analysis
Martina Vittorietti, Sergio Mazzola, Claudio Costantino, Daniele Domenico De Bella, Santo Fruscione, Nicole Bonaccorso, Martina Sciortino, Davide Costanza, Miriam Belluzzo, Alessandra Savatteri, Fabio Tramuto, Paolo Contiero, Giovanna Tagliabue, Palmira I
Frontiers in Oncology.2023;[Epub] CrossRef
Breast implant-associated anaplastic large cell lymphoma: a case report with a history of spontaneously resolved late seroma
Do Yeon Kim, Joon Hur, Woo Yeon Han, Kyunghyun Min, Jong Won Lee, Jin Sup Eom, Hyun Ho Han, Eun Key Kim
Archives of Aesthetic Plastic Surgery.2021; 27(4): 143. CrossRef
Comment on “Breast implant-associated anaplastic large cell lymphoma: the first South Korean case”
Il-Kug Kim, Tae Gon Kim
Journal of Pathology and Translational Medicine.2021; 55(6): 419. CrossRef

Original Articles

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression: Young Wha Koh, Jae-Ho Han, Seong Yong Park, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh; J Pathol Transl Med. 2017;51(2):152-158. Published online February 21, 2017; DOI: https://doi.org/10.4132/jptm.2016.11.03

9,182 View
234 Download
19 Web of Science
18 Crossref

Abstract PDF

Background
Glucose transporter type 1 (GLUT1) expression is linked to glucose metabolism and tissue hypoxia. A recent study reported that GLUT1 was significantly associated with programmed death ligand 1 (PD-L1) as a therapeutic target in relapsed or refractory classical Hodgkin’s lymphoma (cHL). The purpose of this study was to measure the expression of GLUT1 and assess its prognostic significance and potential relationships with PD-L1, programmed death ligand 2 (PD-L2), and programmed death-1 (PD-1) expressions in cHL. Methods: Diagnostic tissues from 125 patients with cHL treated with doxorubicin, bleomycin, vinblastine, and dacarbazine were evaluated retrospectively via immunohistochemical analysis of GLUT1, PD-L1, PD-L2, and PD-1 expression. Results: The median follow-up time was 4.83 years (range, 0.08 to 17.33 years). GLUT1, PD-L1, PD-L2, and PD-1 were expressed in 44.8%, 63.2%, 9.6%, and 13.6% of the specimens, respectively. Positive correlations were found between GLUT1 and PD-L1 expression (p = .004) and between GLUT1 and PD-L2 expression (p = .031). GLUT1 expression in Hodgkin/Reed-Sternberg (HRS) cells was not associated with overall survival or event-free survival (EFS) in the entire cohort (p = .299 and p = .143, respectively). A subgroup analysis according to the Ann Arbor stage illustrated that GLUT1 expression in HRS cells was associated with better EFS in advanced-stage disease (p = .029). A multivariate analysis identified GLUT1 as a marginally significant prognostic factor for EFS (p = .068). Conclusions: This study suggests that GLUT1 expression is associated with better clinical outcomes in advanced-stage cHL and is significantly associated with PD-L1 and PD-L2 expressions.

Citations

Citations to this article as recorded by

Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma
Yuyang Pang, Tingxun Lu, Zijun Y. Xu-Monette, Ken H. Young
International Journal of Molecular Sciences.2023; 24(6): 5493. CrossRef
Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
Kun Wang, Xiaoyong Dai, Albert Yu, Chunyan Feng, Kewei Liu, Laiqiang Huang
Journal of Experimental & Clinical Cancer Research.2022;[Epub] CrossRef
TIMP-1 Dependent Modulation of Metabolic Profiles Impacts Chemoresistance in NSCLC
Wei Xiao, Pankaj Ahluwalia, Lan Wang, John Howard, Ravindra Kolhe, Amyn M. Rojiani, Mumtaz V. Rojiani
Cells.2022; 11(19): 3036. CrossRef
Hypoxia-related tumor environment correlated with immune infiltration and therapeutic sensitivity in diffuse large B-cell lymphoma
Chen Liu, Lin Liu
Frontiers in Genetics.2022;[Epub] CrossRef
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images
Wei Mu, Lei Jiang, Yu Shi, Ilke Tunali, Jhanelle E Gray, Evangelia Katsoulakis, Jie Tian, Robert J Gillies, Matthew B Schabath
Journal for ImmunoTherapy of Cancer.2021; 9(6): e002118. CrossRef
Tumor immunity is related to 18F‐FDG uptake in thymic epithelial tumor
Hisao Imai, Kyoichi Kaira, Kosuke Hashimoto, Hiroyuki Nitanda, Ryo Taguchi, Akitoshi Yanagihara, Tetsuya Umesaki, Ou Yamaguchi, Atsuto Mouri, Tomonori Kawasaki, Masanori Yasuda, Kunihiko Kobayashi, Hirozo Sakaguchi, Ichiei Kuji, Hiroshi Kagamu
Cancer Medicine.2021; 10(18): 6317. CrossRef
Transcutaneous Carbon Dioxide Decreases Immunosuppressive Factors in Squamous Cell Carcinoma In Vivo
Nanae Yatagai, Takumi Hasegawa, Rika Amano, Izumi Saito, Satomi Arimoto, Daisuke Takeda, Yasumasa Kakei, Masaya Akashi, Peter J. Oefner
BioMed Research International.2021; 2021: 1. CrossRef
Current Role of Functional Imaging in the Management of Lymphoma
Bruce D. Cheson, Michel Meignan
Current Oncology Reports.2021;[Epub] CrossRef
Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma
Maria Togo, Takehiko Yokobori, Kimihiro Shimizu, Tadashi Handa, Kyoichi Kaira, Takaaki Sano, Mariko Tsukagoshi, Tetsuya Higuchi, Satoshi Yokoo, Ken Shirabe, Tetsunari Oyama
British Journal of Cancer.2020; 122(11): 1686. CrossRef
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang, Jie Wang, Xiangying Deng, Fang Xiong, Junshang Ge, Bo Xiang, Xu Wu, Jian Ma, Ming Zhou, Xiaoling Li, Yong Li, Guiyuan Li, Wei Xiong, Can Guo, Zhaoyang Zeng
Molecular Cancer.2019;[Epub] CrossRef
Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer
Norimitsu Kasahara, Kyoichi Kaira, Koichi Yamaguchi, Hiroaki Masubuchi, Hiroaki Tsurumaki, Kenichiro Hara, Yasuhiko Koga, Reiko Sakurai, Tetsuya Higuchi, Tadashi Handa, Tetsunari Oyama, Takehiko Yokobori, Kimihiro Shimizu, Takayuki Asao, Takeshi Hisada
Lung Cancer.2019; 134: 180. CrossRef
MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance
Barbara Marengo, Ombretta Garbarino, Andrea Speciale, Lorenzo Monteleone, Nicola Traverso, Cinzia Domenicotti
Oxidative Medicine and Cellular Longevity.2019; 2019: 1. CrossRef
Sustain, Adapt, and Overcome—Hypoxia Associated Changes in the Progression of Lymphatic Neoplasia
Orsolya Matolay, Gábor Méhes
Frontiers in Oncology.2019;[Epub] CrossRef
Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma
Norimitsu Kasahara, Kyoichi Kaira, Pinjie Bao, Tetsuya Higuchi, Yukiko Arisaka, Bilguun Erkhem-Ochir, Noriaki Sunaga, Yoichi Ohtaki, Toshiki Yajima, Takayuki Kosaka, Tetsunari Oyama, Takehiko Yokobori, Takayuki Asao, Masahiko Nishiyama, Yoshito Tsushima,
Lung Cancer.2018; 119: 71. CrossRef
High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
Xiaofang Guo, Juan Wang, Jietian Jin, Hao Chen, Zijun Zhen, Wenqi Jiang, Tongyu Lin, Huiqiang Huang, Zhongjun Xia, Xiaofei Sun
Translational Oncology.2018; 11(3): 779. CrossRef
Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy
Margarita Kirienko, Martina Sollini, Arturo Chiti
Clinical and Translational Imaging.2018; 6(6): 417. CrossRef
New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2017
J. Han van Krieken
Journal of Hematopathology.2017; 10(1): 25. CrossRef
Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior
David J. Pinato, James R. Black, Sebastian Trousil, Roberto E. Dina, Pritesh Trivedi, Francesco A. Mauri, Rohini Sharma
OncoImmunology.2017; 6(11): e1358332. CrossRef

Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases: Su-Jin Shin, Hyangsin Lee, Geunyoung Jung, Minchan Gil, Hosub Park, Young Soo Park, Dok Hyun Yoon, Cheolwon Suh, Chan-Jeoung Park, Jooryung Huh, Chan-Sik Park; Korean J Pathol. 2014;48(3):209-216. Published online June 26, 2014; DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.3.209

7,499 View
80 Download
9 Crossref

Abstract PDF

Background

Multiple myeloma (MM) is a heterogeneous and ultimately fatal disease. Risk stratification using prognostic biomarkers is crucial to individualize treatments. We sought to investigate the role of CD99, a transmembrane protein highly expressed in many hematopoietic cells including subpopulations of normal and neoplastic plasma cells, for MM risk stratification.

Methods

CD99 expression was measured in paraffin samples of bone marrow and extramedullary biopsies of 170 patients with MM. Patients were divided into those with high score (moderately and strongly positive) and low score (negative and weakly positive), with all staining being cytoplasmic and/or membranous.

Results

High anti-CD99 immunostaining was observed in 72 of 136 (52.9%) bone marrow biopsies and 24 of 87 (27.6%) extramedullary biopsies in MM. High CD99 expression of extramedullary specimens was associated with significantly longer overall survival (OS; p=.016). High CD99 expression of extramedullary specimens was also associated with better prognosis in the nonautologous stem cell transplantation group of MM patients (p=.044). In multivariate analysis, International Staging System stage was an independent prognostic factor, whereas CD99 expression was no longer statistically significant.

Conclusions

Expression of CD99 in extramedullary specimens was correlated with longer OS, suggesting that CD99 may be a helpful immunohistochemical marker for risk stratification.

Citations

Citations to this article as recorded by

Cell Adhesion Molecule CD99 in Cancer Immunotherapy
Feng Yu, Guodong Liu, Hailing Zhang, Xiaoyan Wang, Zhi Wu, Qinggang Xu, Yan Wu, Dongfeng Chen
Current Molecular Medicine.2023; 23(10): 1028. CrossRef
Detection of Circulating Tumor Plasma Cells in Monoclonal Gammopathies: Methods, Pathogenic Role, and Clinical Implications
Luzalba Sanoja-Flores, Juan Flores-Montero, Martín Pérez-Andrés, Noemí Puig, Alberto Orfao
Cancers.2020; 12(6): 1499. CrossRef
Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms
Qi Gao, Venkata Yellapantula, Maly Fenelus, Janine Pichardo, Lu Wang, Ola Landgren, Ahmet Dogan, Mikhail Roshal
Modern Pathology.2018; 31(6): 881. CrossRef
EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma
Gregory W Charville, Wei-Lien Wang, Davis R Ingram, Angshumoy Roy, Dafydd Thomas, Rajiv M Patel, Jason L Hornick, Matt van de Rijn, Alexander J Lazar
Modern Pathology.2017; 30(9): 1312. CrossRef
Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients
Eun Ji Oh, Eun Kyung Kim, Woo Ick Yang, Sun Och Yoon
Leukemia & Lymphoma.2016; 57(8): 1921. CrossRef
CD99 Is Strongly Expressed in Basal Cells of the Normal Adult Epidermis and Some Subpopulations of Appendages: Comparison with Developing Fetal Skin
Gawon Choi, Jin Roh, Chan-Sik Park
Journal of Pathology and Translational Medicine.2016; 50(5): 361. CrossRef
Towards Stratified Medicine in Plasma Cell Myeloma
Philip Egan, Stephen Drain, Caroline Conway, Anthony Bjourson, H. Alexander
International Journal of Molecular Sciences.2016; 17(10): 1760. CrossRef
Human Myeloma Cell Lines Induce Osteoblast Downregulation of CD99 Which Is Involved in Osteoblast Formation and Activity
Angela Oranger, Giacomina Brunetti, Claudia Carbone, Graziana Colaianni, Teresa Mongelli, Isabella Gigante, Roberto Tamma, Giorgio Mori, Adriana Di Benedetto, Marika Sciandra, Selena Ventura, Katia Scotlandi, Silvia Colucci, Maria Grano
Journal of Immunology Research.2015; 2015: 1. CrossRef
CD99 regulates CXCL12-induced chemotaxis of human plasma cells
Minchan Gil, Hyo-Kyung Pak, A-Neum Lee, Seo-Jung Park, Yoonkyung Lee, Jin Roh, Hyunji Lee, Yoo-Sam Chung, Chan-Sik Park
Immunology Letters.2015; 168(2): 329. CrossRef

Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients with Multiple Myeloma: Su-Jin Shin, Jin Roh, Misung Kim, Min Jung Jung, Young Wha Koh, Chan-Sik Park, Dok Hyun Yoon, Cheolwon Suh, Chan-Jeong Park, Hyun Sook Chi, Jooryung Huh; Korean J Pathol. 2013;47(6):526-533. Published online December 24, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.6.526

11,137 View
86 Download
24 Crossref

Abstract PDF

Background

Absolute lymphocyte count (ALC) in peripheral blood has recently been reported to be an independent prognostic factor in multiple myeloma (MM). Previous studies indicated that the absolute monocyte count (AMC) in peripheral blood reflects the state of the tumor microenvironment in lymphomas. Neither the utility of the AMC nor its relationship with ALC has been studied in MM.

Methods

The prognostic value of ALC, AMC, and the ALC/AMC ratio at the time of diagnosis was retrospectively examined in 189 patients with MM.

Results

On univariate analysis, low ALC (<1,400 cells/µL), high AMC (≥490 cells/µL), and low ALC/AMC ratio (<2.9) were correlated with worse overall survival (OS) (p=.002, p=.038, and p=.001, respectively). On multivariate analysis, the ALC/AMC ratio was an independent prognostic factor (p=.047), whereas ALC and AMC were no longer statistical significant. Low ALC, high AMC, and low ALC/AMC ratio were associated with poor prognostic factors such as high International Staging System stage, plasmablastic morphology, hypoalbuminemia, and high β2-microglobulin.

Conclusions

Univariate analysis demonstrated that changes in ALC, AMC, and the ALC/AMC ratio are associated with patient survival in MM. Multivariate analysis showed that, of these factors, the ALC/AMC ratio was an independent prognostic factor for OS.

Citations

Citations to this article as recorded by

Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer
Xiaoming Wang, Dayu Chen, Yuyan Ma, Dongping Mo, Feng Yan
Clinical and Translational Oncology.2024; 26(8): 1934. CrossRef
Descriptive analysis and prognostic factors in cats with myeloma‐related disorders: A multicenter retrospective study of 50 cases
Lorris Lecot, Isabelle Desmas‐Bazelle, Sarah Benjamin, Pauline De Fornel, Frédérique Ponce, Matthew Kornya, Loïc Desquilbet, Claire Beaudu‐Lange, Catherine Ibisch, David Sayag, Ghita Benchekroun, Jérémy Béguin
Journal of Veterinary Internal Medicine.2024; 38(3): 1693. CrossRef
Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling
Rahul Banerjee, Kara I. Cicero, Sarah S. Lee, Andrew J. Cowan
Frontiers in Oncology.2023;[Epub] CrossRef
Normal Absolute Monocyte Count in Combination with Normal/High Absolute Lymphocyte Count at the Time of Relapse is Associated with Improved Survival in Patients with Early Relapsed Acute Myeloid Leukemia
Yu Zhang, Kanchun Dai, Qianying Zhang, Yisha Huang, Yiyun Feng, Deeksha Bhardwaj, Kang Yu, Jianhua Feng
Cancer Investigation.2021; 39(6-7): 550. CrossRef
Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
Francesca Cottini, Ying Huang, Nita Williams, Naresh Bumma, Abdullah M. Khan, Maria Chaudhry, Srinivas Devarakonda, Yvonne A. Efebera, Don M. Benson, Ashley E. Rosko
Frontiers in Oncology.2021;[Epub] CrossRef
Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis
Xinwen Zhang, Jialin Duan, Zhenyu Wen, Hao Xiong, Xiaomin Chen, Yang Liu, Kunyu Liao, Chunlan Huang
Frontiers in Oncology.2021;[Epub] CrossRef
Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant
Karen Sweiss, Jonathan Lee, Nadim Mahmud, Gregory S. Calip, Youngmin Park, Dolores Mahmud, Damiano Rondelli, Pritesh R. Patel
Bone Marrow Transplantation.2020; 55(1): 199. CrossRef
Low absolute CD4+ T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma
Yan Gu, Yuanyuan Jin, Jie Ding, Wu Yujie, Qinglin Shi, Xiaoyan Qu, Sishu Zhao, Jianyong Li, Chen Lijuan
Leukemia & Lymphoma.2020; 61(8): 1869. CrossRef
Normal Absolute Monocyte Count at the Time of Relapse is Associated with Improved Survival After First Salvage Therapy in Adult Patients with Early Relapsed B-Lineage Acute Lymphoblastic Leukemia

Yi-fen Shi, Na Wang, Zi-yang Huang, Rong-rong Chen, Yi-sha Huang, Yi-yi Zhu, Chong-yun Xing, Bin Liang, Kang Yu, Jian-hua Feng
Cancer Management and Research.2020; Volume 12: 7097. CrossRef
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma
Moritz Binder, S. Vincent Rajkumar, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Angela Dispenzieri, Yi L. Hwa, Amie Fonder, Miriam Hobbs, Suzanne R. Hayman, Steven R. Zeldenrust, John A. Lust, Stephen J. Russell, Nelson Leung, Prashant Kapoor, Ronal
American Journal of Hematology.2019; 94(3): 306. CrossRef
Effect of absolute monocyte count post-transplant on the outcome of patients with acute myeloid leukemia undergoing myeloablative allogeneic hematopoietic stem cell transplant with busulfan and cyclophosphamide conditioning
Liyuan Tang, Na Wang, Chongyun Xing, Qiang Zhuang, Bin Liang, Lan Sun, Yi Chen, Yan Qian, Zhijian Shen, Songfu Jiang, Kang Yu, Jianhua Feng
Leukemia Research.2018; 69: 60. CrossRef
A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified
Qian Li, Shuang Gao, Jing Ma, Su Liu, Yuanfang Yue, Lin Chen, Han Li, Xue Wang, Dongying Li, Zeng Cao, Zhigang Zhao, Xiaofang Wang, Yong Yu, Yizhuo Zhang, Yafei Wang
Leukemia Research.2018; 73: 5. CrossRef
Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma
Ying Tian, Yue Zhang, Wan-Qiu Zhu, Xiao-Lei Chen, He-Bing Zhou, Wen-Ming Chen
BioMed Research International.2018; 2018: 1. CrossRef
Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma
T Dosani, F Covut, R Beck, J J Driscoll, M de Lima, E Malek
Blood Cancer Journal.2017; 7(6): e579. CrossRef
Lymphocyte-to-monocyte ratio can predict mortality in pancreatic adenocarcinoma
Gurshawn Singh, Ammar Nassri, David Kim, Hong Zhu, Zeeshan Ramzan
World Journal of Gastrointestinal Pharmacology and Therapeutics.2017; 8(1): 60. CrossRef
Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma – an analysis from the Austrian Myeloma Registry
Wolfgang Willenbacher, Ella Willenbacher, Claudia Zelle-Rieser, Rainer Biedermann, Roman Weger, Karin Jöhrer, Andrea Brunner
Leukemia & Lymphoma.2016; 57(6): 1478. CrossRef
Absolute lymphocyte count as a prognostic marker in newly diagnosed multiple myeloma patients
C. Suriu, L. Akria, D. Azoulay, E. Shaoul, M. Barhoum, A. Braester
International Journal of Laboratory Hematology.2016;[Epub] CrossRef
The Peripheral Blood Mononuclear Cell Count Is Associated With Bone Health in Elderly Men
Xianfeng Lin, Hejun Yu, Chenchen Zhao, Yu Qian, Dun Hong, Kangmao Huang, Jian Mo, An Qin, Xiangqian Fang, Shunwu Fan
Medicine.2016; 95(15): e3357. CrossRef
Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis
Liangyou Gu, Hongzhao Li, Luyao Chen, Xin Ma, Xintao Li, Yu Gao, Yu Zhang, Yongpeng Xie, Xu Zhang
Oncotarget.2016; 7(22): 31926. CrossRef
Do lymphocytes count in myeloma? Are we absolutely sure?
Tamar Tadmor
Leukemia & Lymphoma.2015; 56(5): 1193. CrossRef
Absolute lymphocyte count is unrelated to overall survival in newly diagnosed elderly patients with multiple myeloma treated with immunomodulatory drugs
Mariasanta Napolitano, Giorgia Saccullo, Roberto Bono, Antonio Branca, Clotilde Cangialosi, Salvatrice Mancuso, Simona Raso, Gerlando Quintini, Maria Grazia Lipari, Francesco Fabbiano, Giorgina Specchia, Alberto Dolce, Francesco Di Raimondo, Sergio Siragu
Leukemia & Lymphoma.2015; 56(5): 1507. CrossRef
Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes
Vivek Naranbhai, Helen A. Fletcher, Rachel Tanner, Matthew K. O'Shea, Helen McShane, Benjamin P. Fairfax, Julian C. Knight, Adrian V.S. Hill
EBioMedicine.2015; 2(11): 1619. CrossRef
Prognostic value of absolute monocyte count in chronic lymphocytic leukaemia
László Szerafin, János Jakó, Ferenc Riskó
Orvosi Hetilap.2015; 156(15): 592. CrossRef
The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer
Michael Stotz, Joanna Szkandera, Tatjana Stojakovic, Julia Seidel, Hellmut Samonigg, Peter Kornprat, Renate Schaberl-Moser, Fridericke Seggewies, Gerald Hoefler, Armin Gerger, Martin Pichler
Clinical Chemistry and Laboratory Medicine (CCLM).2015;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search